Blood Test Identifying Methylation Process Could Hold Key for Treating Cancers

by Reshma Anand on  March 15, 2016 at 12:39 PM Research News
RSS Email Print This Page Comment
Font : A-A+

An experimental blood test based on signatures of DNA from dying cells may one day be able to detect a range of diseases including cancer and multiple sclerosis, said researchers.
Blood Test Identifying Methylation Process Could Hold Key for Treating Cancers
Blood Test Identifying Methylation Process Could Hold Key for Treating Cancers

The work, described in the Proceedings of the National Academy of Sciences, a peer-reviewed US journal, is still in its early stages, but opens up vast possibilities, the study authors said.

"We view this is as a breakthrough with huge potential, but it will not be realized very soon," said co-author Yuval Dor, a professor at the Hebrew University of Jerusalem.

"We are working hard on this but this is far from clinical use," Dor said in an email to AFP.

So far, the method has been tested on 320 patients and controls, and has shown success in finding diseases such as pancreatic cancer, pancreatitis, diabetes, traumatic brain injury and multiple sclerosis.

When cells die, it can mean a disease is just beginning to take hold in the body -- perhaps a tumor is forming, or an autoimmune or neurodegenerative illness.

Scientists have already known for some time that dying cells release fragmented DNA into the circulating blood.

The new method can identify a unique chemical modification called methylation. These methylation patterns reveal the specific identity of cells.

"Our work demonstrates that the tissue origins of circulating DNA can be measured in humans," said co-author Ruth Shemer of the Hebrew University.

"This represents a new method for sensitive detection of cell death in specific tissues, and an exciting approach for diagnostic medicine," she said.

Researchers stressed that far more work is needed before the test can be brought to the public. Also, the range of diseases that can be detected is small, so far.

And it remains unclear how much the testing might cost. Dor said the technology is based on next-generation DNA sequencing, which is becoming less expensive every year.

"I expect the cost will not be a major factor," Dor said. "There are still technical improvements needed, and more testing on larger populations, in particular in a setting that can actually predict disease."

Source: AFP

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

Related Links

More News on:

Thalassemia Varicocele Quiz on Depression Promote Your Health with Nutrition Supplements Testicle Pain - Symptom Evaluation Blood in Stools - Symptom Evaluation Bombay Blood Group 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement
Advertisement

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive